Qualigen Therapeutics Inc (NASDAQ:QLGN) currently has a daily average trading volume of 12.75M but it saw 883377 shares traded in last market. With a market cap of 4.40M USD, the company’s current market price of $0.16 came rising about 4.97 while comparing to the previous closing price of $0.16. In past 52 weeks, the stock remained buoying in the range of price level as high as $1.10 and as low as $0.14. In the recent trading on the day, stock has struck highest price mark of $0.1509 while lowest mark touched by it was $0.175.
Taking a look at 20-day trading activity of Qualigen Therapeutics Inc (QLGN) gives us an average price of $0.1855, while its current price level is -85.21% below from 52-week high level whereas it is 15.39% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.2231 while that of 200 days or SMA-200 reads an average of $0.3654. A closer look into the stock’s movement over the week reveals that its volatility is standing at 9.25% during that period while stretching the period over a month that decreases to 8.46%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 36.63 which implies that the stock is in neutral territory.
Over the week, QLGN’s stock price is moving -0.79% down while it is -18.81% when we observe its performance for the past one month. Year-to-date it is -70.42% down and over the past year, the stock is showing a downside performance of -82.87%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -1.1 beat the consensus estimate of -1.6 for the same. The company is expected to be releasing its next quarterly report in October, for which analysts forecasted an EPS of 0 while estimate for next year EPS is 0.
Currently, Qualigen Therapeutics Inc’s total number of outstanding shares is 27.02M. Company’s return on equity (ROE) at -1656.23%. Stock’s beta reads -0.78. Its return on asset (ROA) is -134.07% on average.
